First authors should submit their poster and optional materials (slides, video recordings, etc.) to ASCO's Speaker Center by June 8, 2026. For security reasons, presentation slides cannot be submitted ...

Regular abstracts are released on ASCO's Digital Program; Late-Breaking Abstracts (LBAs) will be released at 7:00 AM (PT) on their day of presentation at the meeting ...

Presentations at the ASCO Annual Meeting 2026 illustrated a strengthening trend toward biomarker-driven, targeted first-line treatments for advanced and metastatic non-small cell lung cancers. Cancers ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas ASCO Guidelines ...

Drug that stops cancer cells hiding and a breakthrough for pancreatic cancer among highlights from Asco conference – but there were also notes of caution Doctors, scientists and researchers shared new ...

Dr Daneng Li reviews ASCO 2026 data in which researchers evaluated the combination of systemic therapy and chemoembolization for the treatment of locally advanced hepatocellular carcinoma. Dr Daneng ...

Pulsatile atebimetinib combined with mGnP achieved 36% ORR and median OS 17.3 months in first-line metastatic PDAC, with few discontinuations and minimal high-grade MEK-associated toxicities.

There were 487 exhibitor booths at the American Society of Clinical Oncology (ASCO)’s 2026 annual meeting, held in Chicago’s McCormick Place. Fierce Pharma Marketing attempted to see each one. Jazz's ...

Above the scientific discussions and deal talks at ASCO 2026, the dark cloud of geopolitics hovered over the Chicago convention center. (Angus Liu/Fierce Pharma) In 2017, a little-known company called ...

ASCO didn’t always look like a massive cityscape of pharma booths with a strong advertising presence. Historically, the heavy focus was on medical affairs, given the conference is mainly attended by ...

RASolute 302 showed daraxonrasib reduced mortality risk by 60% versus chemotherapy in previously treated metastatic PDAC, with median OS 13.2 versus 6.7 months. OPTIMA found Prosigna-defined low-risk ...